Recent 8-K filings for MREO

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 12, 2026 12:56 UTC earnings item 2.02item 2.01item 9.01

  Mereo BioPharma Q1 net loss $6.7M; setrusumab Phase 3 fails primary endpoint, regulator engagement begun

• May 12, 2026 11:33 UTC earnings item 2.02item 9.01

  Mereo BioPharma Q1 2026 net loss $6.7M; setrusumab regulatory dialogue initiated for pediatric OI

source · MREO on sec.gov